Session IV: Dyslipidemia/Atherosclerosis/Thrombosis
Too Little, Too Late? Rethinking Primary Prevention Strategies for ASCVD
This activity is multi-supported by educational grants from Arrowhead Pharmaceuticals, Inc., Esperion Therapeutics, Inc., and Novartis Pharmaceuticals Corporation